
Sign up to save your podcasts
Or
Irritable Bowel Syndrome (IBS) is a common disorder that greatly affects quality of life. Several medications have been approved for use in IBS – both constipation (IBS-C) and diarrhea (IBS-D). The American Gastroenterological Association just released guidelines provide evidence-based recommendations for patients.
The GameChanger
In the last 10 years several pharmacotherapies have been FDA approved for both constipation IBS-C) and IBS-D. Updated guidelines from the AGA review the literature surrounding these and other therapies for evidenced based guidelines update. For example, secretagogues such as linactolide are now first line treatment after PEG laxatives for IBS-C
Show Segments
00:00 – Introduction
01:28 – Irritable Syndrome (IBS) Bowel Background
04:04 – AGA Evidence-Based Recommendations
06:33 – IBS-D Recommendations
14:29 – IBS – D and IBS – C Recommendations
17:39 – IBS – C Recommendations
26:54 – Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
References and resources:
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation
Redeem your CPE or CME credit
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Continuing Education Information:
Learning Objectives:
1. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Constipation
2. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Diarrhea
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-282-H01-P
Initial release date: 08/15/22
Expiration date: 08/15/2023
Additional CPE & CME details can be found here
Follow CEimpact on Social Media:
LinkedIn
Instagram
4.8
1616 ratings
Irritable Bowel Syndrome (IBS) is a common disorder that greatly affects quality of life. Several medications have been approved for use in IBS – both constipation (IBS-C) and diarrhea (IBS-D). The American Gastroenterological Association just released guidelines provide evidence-based recommendations for patients.
The GameChanger
In the last 10 years several pharmacotherapies have been FDA approved for both constipation IBS-C) and IBS-D. Updated guidelines from the AGA review the literature surrounding these and other therapies for evidenced based guidelines update. For example, secretagogues such as linactolide are now first line treatment after PEG laxatives for IBS-C
Show Segments
00:00 – Introduction
01:28 – Irritable Syndrome (IBS) Bowel Background
04:04 – AGA Evidence-Based Recommendations
06:33 – IBS-D Recommendations
14:29 – IBS – D and IBS – C Recommendations
17:39 – IBS – C Recommendations
26:54 – Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
References and resources:
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation
Redeem your CPE or CME credit
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Continuing Education Information:
Learning Objectives:
1. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Constipation
2. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Diarrhea
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-282-H01-P
Initial release date: 08/15/22
Expiration date: 08/15/2023
Additional CPE & CME details can be found here
Follow CEimpact on Social Media:
LinkedIn
Instagram
107 Listeners
494 Listeners
43,337 Listeners
12,599 Listeners
3,320 Listeners
1,111 Listeners
717 Listeners
3,476 Listeners
9,277 Listeners
1,213 Listeners
1,301 Listeners
2,030 Listeners
4,456 Listeners
2,030 Listeners
19,441 Listeners